

PB 108 of 2012

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 9)¹

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the *National Health Act 1953*.

Dated 11th December 2012

FELICITY McNEILL

First Assistant Secretary Pharmaceutical Benefits Division Department of Health and Ageing

1 Name of Instrument

(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 9).

(2) This Instrument may also be cited as PB 108 of 2012.

2 Commencement

This Instrument commences on 1 January 2013.

3 Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

Schedule 1 amends the *National Health* (*Listing of Pharmaceutical Benefits*) *Instrument 2012* (PB 71 of 2012).

Schedule 1 Amendments

[1] Schedule 1, entry for Betamethasone

	Ointment 500 micrograms (as valerate) per g, 15 g	Application	Betnovate 1/2	QA	MP NP	C1422		1	1	1
			Cortival 1/2	FM	MP NP	C1422		1	1	1
	Schedule 1, entry for Bicalutamide omit from the column headed "Responsible d	Person" for the b	rand "Cosudex":	sz	substit	ute: AP				
	Schedule 1, entry for Clopidogrel in the omit from the column headed "Circumstance"		••••	-	-	! Winthrop", "Is	scover" and "	Plavix''		
	C3146 C3879									
	insert in numerical order:									
	C4165 C4166									
]	Schedule 1, entry for Clopidogrel in the insert in numerical order in the column head		•		vix 75":					
	C4165 C4166									
]	Schedule 1, entry for Famciclovir in the insert in the columns in the order indicated,		• -		•	-	ats 5]			
			Famciclovir generichealth 50		MP NP	C3626 C3627 C3628 C3629		56	5	56

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Fendex ER	AF	MP NP	30	5	30	

[7]	Schedule 1, entry for Fentanyl in the form Transde insert in the columns in the order indicated, and in alphabe	•	-	headed "B	Prand":				
		Dutran 12	GM	MP NP	C1062	5	0	5	
8]	Schedule 1, entry for Fentanyl in the form Transde	rmal patch 4.12	5 mg						
	insert in the columns in the order indicated, and in alphabe	tical order for the	column	headed "B	Prand":				
		Dutran 25	GM	MP NP	C1062	5	0	5	
9]	Schedule 1, entry for Fentanyl in the form Transde	rmal patch 8.25	mg						
	insert in the columns in the order indicated, and in alphabe	tical order for the	column	headed "B	Prand":				
		Dutran 50	GM	MP NP	C1062	5	0	5	
10]	Schedule 1, entry for Fentanyl in the form Transde	rmal patch 12.3	75 mg						
-	insert in the columns in the order indicated, and in alphabe	tical order for the	column	headed "B	Brand":				
		Dutran 75	GM	MP NP	C1062	5	0	5	
11]	Schedule 1, entry for Fentanyl in the form Transde	rmal patch 16.5	mg						
-	insert in the columns in the order indicated, and in alphabe	•	-	headed "B	Prand":				
		Dutran 100	GM	MP NP	C1062	5	0	5	
[12]	Schedule 1, entry for Fluoxetine in the form Capsu	lle 20 mg (as hy	drochlo	oride)					
-	omit from the column headed "Brand": Auscap	substitute:		cap Aspe	en				
[13]	Schedule 1, entry for Lamotrigine in the form Table	et 25 mg							
	insert in the columns in the order indicated, and in alphabe	tical order for the	column	headed "B	Prand":				
		Lamotrigine Aspen 25	AS	MP NP	C1426	56	5	56	
[14]	Schedule 1, entry for Lamotrigine in the form Table	et 100 mg							
	insert in the columns in the order indicated, and in alphabe	tical order for the	column	headed "B	Prand":				
		Lamotrigine Aspen 100	AS	MP NP	C1426	56	5	56	
15]	Schedule 1, entry for Macrogol 3350 in the form Po (a) <i>omit:</i>	owder for oral so	olution	510 g					
		your pharmacy Clear Laxative	OY	MP NP	C1263 C1613 P3643 C2693 C2823 C3642 C3643	2	0	1	

(b) *omit*:

			your pharmacy Clear Laxative	ΟY	MP NP	C1263 C1613 C2693 C2823 C3642 C3643	P3642	2	3	1	
	(c)	omit:									
			your pharmacy Clear Laxative	OY	MP NP	C1263 C1613 C2693 C2823 C3642 C3643	P1263 P1613 P2693 P2823	1	5	1	
6]		lule 1, entry for Mirtazapine in each of the f ablet 45 mg (orally disintegrating)	orms: Tablet 15 mg	(orall	ly disinteg	rating); Table	et 30 mg (or	ally di	sintegra	ting);	
	omit fr	rom the column headed "Brand": Mirtazapir	ne Pfizer substitu	te:	Mirtaza	pine Dispers	ible Pfizer				
17]	Schee	dule 1, entry for Mycophenolic Acid in the f	orm Capsule contai	ining	mycopher	nolate mofetil	250 mg				
	(a)	omit:									
			Cellplant	WQ	MP	C1765 C1766		300	3	100	
	(b)	omit:									
						04050 04054		600	F	100	C(100
			Cellplant	WQ	MP See Note 1	C1650 C1651 C3355 C3356		000	5	100	0(100
[18]		dule 1, entry for Mycophenolic Acid in the f			See Note 1	C3355 C3356	500 mg	000	5		0(100
18]	Schee (a)	dule 1, entry for Mycophenolic Acid in the f <i>omit:</i>	orm Capsule conta	ining	See Note 1	C3355 C3356	500 mg				
18]				ining	See Note 1	C3355 C3356	500 mg	150	3	50	
[18]			orm Capsule conta	ining	See Note 1	C3355 C3356	500 mg				
[18]	(a)	omit:	orm Capsule conta	ining WQ	See Note 1	C3355 C3356	500 mg				C(100)
[18]	(a) (b)	omit: omit: lule 1, entry for Pantoprazole in the form Ta	Cellplant	ining WQ WQ	See Note 1 mycopher MP MP See Note 1	C3355 C3356 nolate mofetil C1765 C1766 C1650 C1651 C3355 C3356		150	3	50	
	(a) (b) Sched	omit: omit: lule 1, entry for Pantoprazole in the form Ta	Cellplant Cellplant Cellplant	ining wa wa d) 40 r	See Note 1 mycopher MP MP See Note 1	C3355 C3356 nolate mofetil C1765 C1766 C1650 C1651 C3355 C3356		150	3	50	
	(a) (b) Sched <i>Repea</i>	omit: omit: dule 1, entry for Pantoprazole in the form Ta	Form Capsule contain Cellplant Cellplant Cellplant ablet (enteric coated son" for the brand "Pa	ining WQ WQ d) 40 r	See Note 1 mycopher MP See Note 1 mg (as soc NZ	C3355 C3356 nolate mofetil C1765 C1766 C1650 C1651 C3355 C3356 lium sesquih	ydrate) <i>[Ma</i>	150	3	50	
	(a) (b) Sched Repea (a) (b)	omit: omit: dule 1, entry for Pantoprazole in the form Tatats 2] omit from the column headed "Responsible Personit from the column headed "Responsible Personit from the column headed "Responsible Personit from the form Tata	Cellplant Cellplant Cellplant ablet (enteric coated son" for the brand "Pa son" for the brand "Pa	ining WQ WQ d) 40 r	MP MP See Note 1 mg (as soc NZ ": NH	C3355 C3356 nolate mofetil C1765 C1766 C1650 C1651 C3355 C3356 lium sesquih substitute: substitute:	ydrate) <i>[Ma</i> TK TE	150 300 x Qua	3 5 ntity 30;	50 50 Number of	
19]	(a) (b) Sched Repea (a) (b) Sched	omit: omit: dule 1, entry for Pantoprazole in the form Tatats 2] omit from the column headed "Responsible Personit from the column headed "Responsible Personit from the column headed "Responsible Personit from the form Tata	Cellplant Cellplant Cellplant ablet (enteric coated son" for the brand "Pa son" for the brand "Pa ablet (enteric coated	ining WQ WQ d) 40 r anto ": antoloc d) 40 r	MP MP See Note 1 mg (as soc NZ ": NH	C3355 C3356 nolate mofetil C1765 C1766 C1650 C1651 C3355 C3356 lium sesquih substitute: substitute:	ydrate) <i>[Ma</i> TK TE	150 300 x Qua	3 5 ntity 30;	50 50 Number of	

5

1]	Scheo	dule 1, entry for Pantoprazole in the form	Tablet (entend coale	u) 20 i	ng (as so	alum sesquin	yuratej			
	(a)	omit from the column headed "Responsible Pe	erson" for the brand "Pa	anto":	NZ	substitute:	ТК			
	(b)	omit from the column headed "Responsible Pe	erson" for the brand "Po	antoloc	:": NH	substitute:	TE			
22]	Sche	dule 1, entry for Rabeprazole in the form ⁻	Tablet containing rab	pepraz	ole sodiu	um 10 mg (ent	eric coated)			
	(a)	omit from the column headed "Brand": F	Parzole 10 substitu	ıte:	Parzo	l 10				
	(b)	insert in the columns in the order indicated, a	nd in alphabetical order	for the	e column he	eaded "Brand":				
			Razit 10	DO	MP NP	C1337 C1533		28	5	28
3]	Scheo Repea	dule 1, entry for Rabeprazole in the form T ats 2]	Fablet containing rab	eprazo	ole sodiu	m 20 mg (ente	ric coated)	[Max	Quantity	30; Number of
	(a)	omit from the column headed "Brand": F	Parzole 20 substitu	ıte:	Parzo	l 20				
	(b)	insert in the columns in the order indicated, a	nd in alphabetical order	for the	e column he	eaded "Brand":				
			Razit 20	DO	MP NP	C1177 C1337 C1533	P1177	30	2	30
	(c)	insert in the columns in the order indicated, a	nd in alphahetical order	for the	e column he	eaded "Brand":				
	(•)		na in alphasetteat stael	<i>joi in</i> e						
	(0)		STADA Rabeprazole	0	MP NP	C1177 C1337 C1533	P1177	30	2	30
4]		dule 1, entry for Rabeprazole in the form T	STADA Rabeprazole	TD	MP NP	C1533				
4]	Scheo	dule 1, entry for Rabeprazole in the form T ats 5]	STADA Rabeprazole	TD epraze	MP NP	C1533 m 20 mg (ente				
4]	Scheo Repea	dule 1, entry for Rabeprazole in the form T ats 5]	STADA Rabeprazole Tablet containing rab	TD eprazo	MP NP ole sodiu Parzo	C1533 m 20 mg (ente I 20				
4]	Scheo Repea (a)	dule 1, entry for Rabeprazole in the form T ats 5] omit from the column headed "Brand": F	STADA Rabeprazole Tablet containing rab	TD epraze ute: for the	MP NP ole sodiu Parzo	C1533 m 20 mg (ente I 20	ric coated)	[Max		
24]	Scheo Repea (a)	dule 1, entry for Rabeprazole in the form T ats 5] omit from the column headed "Brand": F	STADA Rabeprazole Fablet containing rabe Parzole 20 substitu nd in alphabetical order Razit 20	TD epraze <i>ite:</i> <i>for the</i> DO	MP NP ole sodiu Parzo e column ha MP NP	C1533 m 20 mg (enter l 20 eaded "Brand": C1177 C1337 C1533	ric coated)	[Max	Quantity	30; Number of
24]	Scheo <i>Repea</i> (a) (b)	dule 1, entry for Rabeprazole in the form T ats 5] omit from the column headed "Brand": F insert in the columns in the order indicated, a	STADA Rabeprazole Fablet containing rabe Parzole 20 substitu nd in alphabetical order Razit 20	TD eprazo ite: for the DO for the	MP NP ole sodiu Parzo e column ha MP NP	C1533 m 20 mg (enter l 20 eaded "Brand": C1177 C1337 C1533	P1337 P1533	[Max 30	Quantity	30; Number of
25]	Schec Repea (a) (b) (c)	dule 1, entry for Rabeprazole in the form T ats 5] omit from the column headed "Brand": F insert in the columns in the order indicated, a	STADA Rabeprazole Fablet containing rabe Parzole 20 substitu nd in alphabetical order Razit 20 nd in alphabetical order STADA Rabeprazole	TD eprazo ite: for the DO for the TD	MP NP ole sodiu Parzo e column he MP NP e column he MP NP	C1533 m 20 mg (enter l 20 eaded "Brand": C1177 C1337 C1533 eaded "Brand": C1177 C1337 C1533	P1337 P1533 P1337 P1533	[Max 30	Quantity	30; Number of 30
	Schec Repea (a) (b) (c)	dule 1, entry for Rabeprazole in the form T ats 5] omit from the column headed "Brand": F insert in the columns in the order indicated, an insert in the columns in the order indicated, an	STADA Rabeprazole Fablet containing rabe Parzole 20 substitu nd in alphabetical order Razit 20 nd in alphabetical order STADA Rabeprazole	TD eprazo ite: for the DO for the TD	MP NP ole sodiu Parzo e column he MP NP e column he MP NP	C1533 m 20 mg (enter l 20 eaded "Brand": C1177 C1337 C1533 eaded "Brand": C1177 C1337 C1533	P1337 P1533 P1337 P1533	[Max 30	Quantity	30; Number of 30
	Scheo Repea (a) (b) (c) Scheo	dule 1, entry for Rabeprazole in the form T ats 5] omit from the column headed "Brand": F insert in the columns in the order indicated, a insert in the columns in the order indicated, and dule 1, entry for Risperidone in the form T	STADA Rabeprazole Fablet containing rabe Parzole 20 substitu nd in alphabetical order Razit 20 nd in alphabetical order STADA Rabeprazole	TD eprazo tte: for the DO for the TD	MP NP ole sodiu Parzo e column he MP NP e column he MP NP	C1533 m 20 mg (enter l 20 eaded "Brand": C1177 C1337 C1533 eaded "Brand": C1177 C1337 C1533	P1337 P1533 P1337 P1533 P1337 P1533 ts 2]	[Max 30 30	Quantity	30; Number of 30
_	Scheo Repea (a) (b) (c) Scheo	dule 1, entry for Rabeprazole in the form T ats 5] omit from the column headed "Brand": F insert in the columns in the order indicated, a insert in the columns in the order indicated, and dule 1, entry for Risperidone in the form T	STADA Rabeprazole Fablet containing rabe Parzole 20 substitu nd in alphabetical order Razit 20 nd in alphabetical order STADA Rabeprazole Fablet 0.5 mg [Max Q Resdone 0.5	TD eprazo ite: for the DO for the TD DUANTIE	MP NP ole sodiu Parzo e column he MP NP e column he MP NP	C1533 m 20 mg (enternation of the second sec	P1337 P1533 P1337 P1533 P1337 P1533 ts 2]	[Max 30 30	Quantity	30; Number of 30 30

[26] Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 5]

(a) omit:

	(a)	omit:								
			Resdone 0.5	CR	MP NP	C1589 C2061 F C3083	P1589	60	5	60
	(b)	insert in the columns in the order indicated	l, and in alphabetical order	for the	e column he	eaded "Brand":				
			Rispericor 0.5	CR	MP NP	C1589 C2061 F C3083	P1589	60	5	60
]	Sche	dule 1, entry for Risperidone in the for	n Tablet 1 mg <i>[Max Qua</i>	antity	60; Numl	ber of Repeats 2	2]			
	(a)	omit:								
			Resdone 1	CR	MP NP	C1589 C2061 F C2272 C3083	P2061 P3083	60	2	60
	(b)	insert in the columns in the order indicated	l, and in alphabetical order	for the	e column he	eaded "Brand":				
			Rispericor 1	CR	MP NP	C1589 C2061 F C2272 C3083	P2061 P3083	60	2	60
8]	Sche	dule 1, entry for Risperidone in the for	m Tablet 1 mg <i>[Max Qua</i>	antity	60; Numl	ber of Repeats	5]			
	(a)	omit:								
			Resdone 1	CR	MP NP	C1589 C2061 F C2272 C3083	P1589 P2272	60	5	60
	(b)	insert in the columns in the order indicated	l, and in alphabetical order	for the	e column he	eaded "Brand":				
			Rispericor 1	CR	MP NP	C1589 C2061 F C2272 C3083	P1589 P2272	60	5	60
9]	Sche	dule 1, entry for Risperidone in the for	n Tablet 2 mg <i>[Max Qua</i>	antity	60; Numl	ber of Repeats 2	2]			
	(a)	omit:								
			Resdone 2	CR	MP NP	C1589 C2272 F C3083	P3083	60	2	60
	(b)	insert in the columns in the order indicated	l, and in alphabetical order	for the	e column he	eaded "Brand":				
			Rispericor 2	CR	MP NP	C1589 C2272 F C3083	23083	60	2	60
D]	Schee (a)	dule 1, entry for Risperidone in the form omit:	m Tablet 2 mg <i>[Max Qua</i>	antity	60; Numl	ber of Repeats s	5]			
-	• •				MP NP	C1589 C2272			5	60

(b) *insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

			Rispericor 2	CR	MP NP	C1589 C2272 P1589 P227 C3083	2 60	5	60	
31]	Sche	dule 1, entry for Risperidone in the form Tab	olet 3 mg							
	(a)	omit:								
			Resdone 3	CR	MP NP	C1589 C2272	60	5	60	
	(b)	insert in the columns in the order indicated, and	in alphabetical order f	or the	e column h	eaded "Brand":				
			Rispericor 3	CR	MP NP	C1589 C2272	60	5	60	
32]	Sche	dule 1, entry for Risperidone in the form Tak	olet 4 mg							
	(a)	omit:								
			Resdone 4	CR	MP NP	C1589 C2272	60	5	60	
	(b)	insert in the columns in the order indicated, and	in alphabetical order f	or the	e column h	eaded "Brand":				
			Rispericor 4	CR	MP NP	C1589 C2272	60	5	60	
33]	Sche	dule 1, entry for Terbinafine in the form Tab	let 250 mg (as hydr	ochl	oride)					
-	(a)	omit:								
			Terbix 250	MI	MP NP	C2191 C2865 P2865 P324 C3244	4 42	0	42	
	(b)	omit:								
			Terbix 250	MI	MP NP	C2191 C2865 P2191 C3244	42	1	42	
[34]	Sche	dule 1, entry for Tramadol in the form Caps	ule containing tram	adol	hydrochl	oride 50 mg				
	(a)	omit:								
			GenRx Tramadol	GX	MP NP	C1497 C1615 P1497	20	0	20	
					PDP	C1497 C1615	20	0	20	
	(b)	omit:								
			GenRx Tramadol	GX	MP NP	C1497 C1615 P1615	20	2	20	
[35]	Sche	dule 1, entry for Tramadol								
_	(a)	omit:								
		Tablet (extended release) containing Oral tramadol hydrochloride 100 mg	Durotram XR	IA	MP NP	C1537	10	0	10	

			Tablet (extended release tramadol hydrochloride 2		Oral	Durotram XR	IA	MP NP	C1537	10	0	10
	(c)	omit:										
			Tablet (extended release tramadol hydrochloride 3		Oral	Durotram XR	IA	MP NP	C1537	10	0	10
6]			entry for Venlafax mg (as hydrochlori		ch of the f	orms: Capsule	e (mod	lified relea	ase) 75 mg (as	hydrochloride);	and Ca	apsule (modified
	omit fr	rom the d	column headed "Brand	d": ST	ADA Venla	afaxine SR	subs	stitute:	STADA Venlaf	axine-SR		
37]	Sche	dule 3										
	omit:											
NH		Nyc	omed Healthcare Pty Lim	nited		55 140 659 374						
	-											
38]	Sche	dule 3,	details relevant to	Responsi	ble person	code NQ						
38]	Schee			Responsi substitute:	-	code NQ da Pharmaceuti	icals A	Australia P	Pty Ltd			
38] 39]	omit:			-	-		icals A	Australia P	Pty Ltd			
-	omit:	Nyco		-	-		icals A	Australia P	Pty Ltd			
39]	omit: Schee	Nyco dule 3		substitute:	-		icals A	Australia P	Pty Ltd			
39] NZ	omit: Schee omit:	Nycc dule 3	omed Pty Ltd s	substitute:	Takeo	da Pharmaceuti	icals A	Australia P	Pty Ltd			
39] NZ	omit: Schee omit:	Nycc dule 3 Nyc dule 3,	omed Pty Ltd s	substitute:	Takeo	da Pharmaceuti	icals A	Australia P	Pty Ltd			
39] NZ 40]	omit: Schee omit: Schee	Nycc dule 3 Nyc dule 3,	omed Pty Ltd s	substitute: ed nt to Resp	Takec	da Pharmaceuti	icals A	Australia P	Pty Ltd			
-	omit: Schee omit: Schee	Nycc dule 3 Nyc dule 3,	omed Pty Ltd s omed Services Pty Limite after details relevan	substitute: ed nt to Resp stralia Pty Ltd	Taked ponsible pe	da Pharmaceuti 15 140 661 123 erson code TD	icals A	Australia P	Pty Ltd			
39] NZ 40] TE TK	omit: Schee omit: Schee insert:	Nycc dule 3 Nyc dule 3, Taki Taki	omed Pty Ltd s omed Services Pty Limite after details relevan eda Pharmaceuticals Aus	substitute: ed nt to Resp stralia Pty Lto stralia Pty Lto	Taked ponsible pe	da Pharmaceuti 15 140 661 123 erson code TD 71 095 610 870	icals A	Australia P	Pty Ltd			
39] NZ 40] TE	omit: Schee omit: Schee insert:	Nycc dule 3 Nyc dule 3, Taki Taki	omed Pty Ltd s omed Services Pty Limite after details relevan eda Pharmaceuticals Aus eda Pharmaceuticals Aus	substitute: ed nt to Resp stralia Pty Lto stralia Pty Lto	Taked ponsible pe	da Pharmaceuti 15 140 661 123 erson code TD 71 095 610 870	icals A	Australia P	Pty Ltd			

C3879		Compliance with Authority Required procedures – Streamlined Authority
		Code 3879

(b) *insert in numerical order following existing text:*

C4165	The treatment must be in combination with aspirin; The treatment must follow insertion of a cardiac stent	Compliance with Authority Required procedures - Streamlined Authority Code 4165
C4166	The treatment must be in combination with aspirin	Compliance with Authority Required procedures - Streamlined Authority Code 4166

¹Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.

See http://www.frli.gov.au.